ClinicalTrials.gg
RecruitingNCT06719024RCTUpdated Dec 5, 2024

Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus

A Phase 2/3 interventional study of Ruxolitinib Cream 1.5% and Aqueous cream in Vitiligo, sponsored by Hospital Authority, Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by Hospital Authority, Hong Kong · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.

Planned enrollment
12th of 14
20 · median 90
Started
2024
the only one that year
Phase 2/3
Only one
of the 14
Registered
10th of 14
by date
Lead sponsor
1 of 14
Hospital Authority, Hong Kong

Among the 14 studies testing ruxolitinib in Vitiligo, this one is the 12th largest by planned enrollment, is the only one that started in 2024, is the only one in phase 2/3, and was the 10th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 95 are open to participants now.

Browse Vitiligo studies →

Open to participants now

5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Vitiligo studies recruiting now, 13 (28%) set no upper age limit and 28 (60%) stop at 75 or younger; 17 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ruxolitinib in Vitiligo, or all of them as a file.
02

Study summary

This trial is a prospective, open-label, single-center, split face randomized controlled study comparing 1.5% topical Ruxolitinib cream twice daily (BD) to aqueous cream in treating non-segmental vitiligo (NSV) of the face and neck in patient previous failed to respond to topical tacrolimus 0.1%. Aqueous cream twice daily application will be used as control group treatment. Patients with stable NSV at least 0.5% of their total body surface area (BSA) on the face and neck, as determined by the fingertip method, are screened. Recruited subjects will be asked to review their impression of change of their lesion by the end of the study using a 7-point scale.

Read the detailed description

Vitiligo is a chronic autoimmune skin disorder marked by the loss of melanocytes, leading to the development of depigmented patches on the skin. In this study, the investigators hypothesis that there is a noticeable difference in responses between using 1.5% ruxolitinib cream applied twice daily (BD) and aqueous cream BD at the end of the trial period. The investigators aim to investigate the efficacy and safety of topical 1.5% topical ruxolitinib cream on non-segmental vitiligo of the face and neck in Chinese patients who previously failed to improve with topical tacrolimus.

03

Conditions studied

  • Vitiligo

Browse trials for

Keywords

  • non-segmental vitiligo
  • randomized controlled trial
  • Chinese
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 85 year old
  • Have a clinical diagnosis of stable non-segmental vitiligo
  • Depigmentation including at least 0.5% of the BSA on the face and neck
  • Previously treated with topical tacrolimus 0.1% BD for at least 3 months without significant response
  • Agree to stop using any topical treatments on face and neck and systemic treatment for vitiligo during the until the trial concludes. Use of over-the-counter products approved by the investigator and camouflage makeup is allowed
  • Both male and female patients must commit to using effective to prevent pregnancy or fathering a child throughout the study
  • Subjects or their legally authorized representative, if applicable, must be able to understand and willing to provide at Screening visit

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse to give consent
  • Presence of different vitiligo types or other skin depigmentation conditions like piebaldism or leprosy, etc.
  • History of using depigmentation treatments other than hydroquinone for vitiligo or pigmentation issues
  • Any skin condition affecting study participation, active skin infections one week before the study starts, issues impacting vitiligo evaluation, or serious health problems limiting involvement or increasing risk
  • Significant medical disease that may hinder use of topical JAK inhibitor, e.g. serious infection, untreated chronic hepatitis, within 5 years except adequately treated non cancer, evidence of or uncontrolled cardiovascular disease, thrombosis including DVT and PE, blood abnormality including significant thrombocytopenia, anaemia ( \<10g/dL) and significant neutropenia, substance misuse
  • Specific treatment use within certain periods before starting (Baseline visit):

    1 week for topical vitiligo treatments 4 weeks for immunomodulators, photosensitizers, oral retinoids, methoxsalen, or 8 weeks for laser or phototherapy on face and neck 12 weeks for biologics

  • Any prior application of topical or oral JAK inhibitors
  • Hemoglobin under 10 g/dL, significant liver dysfunction, and/or evidence of infection or positive for HIV antibodies at initial screening or current acquired, common variable or inherited, primary or secondary immunodeficiency
  • Females of who are pregnant, during breastfeeding period, or those planning pregnancy during the study
  • Those unlikely or unable to comply with the requirements of this study protocol
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Ruxolitinib cream

    a thin layer of the assigned topical to the selected lesions twice daily

    Drug: Ruxolitinib Cream 1.5%

  • Placebo comparator
    Aqueous cream

    a thin layer of the assigned topical to the selected lesions twice daily

    Drug: Aqueous cream

Interventions

  • DrugRuxolitinibStudies of RuxolitinibRuxolitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications

  • DrugAqueous cream

    a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications

06

What researchers measure

Primary outcomes

  1. Degree of repigmentation at week 24 comparing to baseline

    Comparing the degree of repigmentation of lesion site between baseline and week 24 with Physician global assessment of the degrees of repigmentation of the vitiligo lesions

    Time frame: week 24

07

Study locations

1 of 1 sites recruiting
  • Queen Mary Hospital, Hospital Authority
    Hong Kong, Hong Kong
    Recruiting
    • YM Lau · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jun 2025, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2024
First posted
Dec 5, 2024
StartActual
Nov 29, 2024
Primary completionEst.
Jun 16, 2025
CompletionEst.
Jan 30, 2026
Last update
Dec 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06719024
Lead sponsor
Hospital Authority, Hong Kong
Responsible party
Yuk Ming Lau (Principal Investigator, Hospital Authority, Hong Kong) — Principal investigator
First posted
Dec 5, 2024
Start date
Nov 29, 2024
Primary completion
Jun 16, 2025 (estimated)
Completion
Jan 30, 2026 (estimated)
Last update
Dec 5, 2024

Study contacts

Research Assistant
Contact
js83213@hku.hk
+85222555885
YM Lau
principal investigator · Queen Mary Hospital, Hospital Authority

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion